Skip to content
Companies

GT Biopharma

Immune cell engagers for leukemia and other blood cancers

Raised to date

$7.2M

of $27.2M offered across 3 Form D filings

Still open
$20M
Investors
6
Last filed
May 28, 2025

About

GT Biopharma, Inc. is a clinical stage biopharmaceutical company dedicated to the advancement of immunotherapy treatments for cancer and other serious diseases. By focusing on the limitations of existing treatments, GT Biopharma aims to provide innovative solutions that are both targeted and effective.

GT Biopharma distinguishes itself through its proprietary TriKE platform, which enhances the cancer-fighting abilities of a patient's own natural killer (NK) cells, offering a potentially more effective treatment modality compared to traditional therapies.

Funding

$20M round, first sold May 2025Nothing sold yetFeb 20252026
Now
  • EquityFiled May 28, 2025Form D
    None sold/ $20M
  • EquityFiled May 27, 2025Form D
    $6M/ $6M
  • EquityFiled Mar 7, 2025Form D
    $1.3M/ $1.3M

Product

GTB-3650

Immunotherapy

GTB-3650 is a TriKE therapeutic agent specifically targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is designed to engage the patient’s immune cells to more effectively target and kill cancer cells, thereby enhancing the therapeutic prospects for patients with challenging forms of blood cancer.

  • Tri-specific engaging mechanism
  • Targets CD33-expressing cells
  • Harnesses patient’s own NK cells

Built for

Patients with difficult-to-treat cancers

People on file